BLISS-LN trial revisited: function matters.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35065691.
- Also identified by DOI 10.1016/j.kint.2021.12.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN) shows belimumab effectively reduced the time to 30% and 40% decreases in estimated glomerular filtration rate and persistent decreases in estimated glomerular filtration rate. Subgroup analysis found belimumab was most effective in proliferative lupus nephritis, and that there was no apparent benefit from the addition of belimumab in those with baseline nephrotic range proteinuria nor in those receiving cyclophosphamide/azathioprine. These results raise questions about trial end points and their relationship to long-term kidney function, the outcome of most importance to patients, caregivers, and health professionals alike.
Medical subject headings
- Lupus Nephritis